A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology

E-ISSN： 1873-4294|12|15|1660-1664

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.12, Iss.15, 2012-08, pp. : 1660-1664

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium

By Onar Arzu Kocak Mehmet Boyett James

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 437-455

Taylor & Francis Ltd

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology

By Comets Emmanuelle Zohar Sarah

Clinical Pharmacokinetics, Vol. 48, Iss. 6, 2009-06 ,pp. : 387-395

Adis International

Access to resources Recommend Favorite

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

By Keizer Ron

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1519-1530

Springer Publishing Company

Access to resources Recommend Favorite